The experimental drug, retatrutide, is being developed by pharmaceutical company Eli Lilly and is being investigated for its powerful impact on weight loss. Despite not yet approved by the FDA, it is considered a ‘triple-agonist’ medication that targets three key metabolic hormone receptors involved in appetite control and energy balance. It is currently undergoing clinical trials and is currently being evaluated in large Phase 3 studies. Unlike other weight management drugs like Ozempic and Wegovy, RetatrUTide may help reduce appetite and slow digestion, which can help users feel full after eating smaller meals. However, its effect on the glucagon hormone, which regulates blood sugar and regulates cardiovascular risk markers, is also significant as obesity is closely linked to health issues linked to type 2 diabetes, heart disease, and fatty liver disease. Despite these benefits, Dr. John Burns, a board-certified plastic surgeon and president at Dallas Plastic Surgery Institute, says it remains unclear whether long-term safety, dosing and side-effect profiles are still being evaluated.